医学
阿司匹林
溶栓
冲程(发动机)
急性中风
心脏病学
内科学
心肌梗塞
组织纤溶酶原激活剂
机械工程
工程类
作者
Sanne M. Zinkstok,Ludo F.M. Beenen,Charles B.L.M. Majoie,Henk A. Marquering,Rob J. de Haan,Yvo B.W.E.M. Roos
出处
期刊:Stroke
[Ovid Technologies (Wolters Kluwer)]
日期:2014-10-01
卷期号:45 (10): 3080-3082
被引量:46
标识
DOI:10.1161/strokeaha.114.006268
摘要
Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage (SICH), without influencing functional outcome at 3 months. The effect of aspirin on early neurological deterioration (END) was explored as a post hoc analysis of the randomized Antiplatelet Therapy in Combination With Recombinant t-PA Thrombolysis in Ischemic Stroke (ARTIS) trial.END, defined as a ≥4 points National Institutes of Health Stroke Scale worsening ≤24 hours after intravenous thrombolysis, was categorized into SICH (ENDSICH) and cerebral ischemia (ENDCI). Multinomial logistic regression was used to assess the effect of aspirin on END.Of the 640 patients, 31 patients (4.8%) experienced END (14 ENDSICH, 17 ENDCI). Aspirin increased the risk of ENDSICH (odds ratio, 3.73; 95% confidence interval, 1.03-13.49) but not of ENDCI (odds ratio, 1.14; 95% confidence interval, 0.44-3.00). After adjustment for other explanatory variables, the association between aspirin and ENDSICH remained significant.In this trial, there is no evidence of an early antithrombotic effect from the addition of aspirin to intravenous thrombolysis in acute ischemic stroke.
科研通智能强力驱动
Strongly Powered by AbleSci AI